The role of the complement system in CNS inflammatory diseases

References

• Mastellos D, Morikis D, Isaacs SN, Holland MC, Strey CW, Lambris JD. Complement: structure, functions, evolution, and viral molecular mimicry. Immunol. Res.27, 367–386 (2003).
   PubMedGoogle Scholar
• Carroll MC. The complement system in regulation of adaptive immunity. Nat. Immunol.5, 981–986 (2004).
   PubMed Web of Science ®Google Scholar
• Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol. Lett.97, 171–179 (2005).
   PubMed Web of Science ®Google Scholar
• Mastellos D, Andronis C, Persidis A, Lambris JD. Novel biological networks modulated by complement. Clin. Immunol.115, 225–235 (2005).
   PubMed Web of Science ®Google Scholar
• Volanakis JE, Frank MM. The Human Complement System in Health and Disease. Marcel Dekker Inc., NY, USA (1998).
   Google Scholar
• Barnum SR. In: Inflammatory Events in Neurodegeneration. Bondy SC, Campbell A (Eds). Prominent Press, Scottsdale, AZ, USA, 139–156 (2001).
   Google Scholar
• Akiyama H, Barger S, Barnum S et al. Inflammation and Alzheimer’s disease. Neurobiol. Aging21, 383–421 (2000).
   PubMed Web of Science ®Google Scholar
• Barnum SR, Szalai AJ. Complement and demyelinating disease: no MAC needed? Brain Res. Rev. (2006) (In Press).
   PubMedGoogle Scholar
• Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol.152, 5477–5484 (1994).
   PubMed Web of Science ®Google Scholar
• Shin ML, Koski CL. In: Myelin: Biology and Chemistry. Martenson RE (Ed.). CRC Press, Boca Raton, FL, USA, 801–831 (1992).
   Google Scholar
• Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol.112, 1–14 (2001).
   PubMed Web of Science ®Google Scholar
• Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol.55, 458–468 (2004).
   PubMed Web of Science ®Google Scholar
• Morariu MA, Dalmasso AP. Experimental allergic encephalomyelitis in cobra venom factor-treated and C4-deficient guinea pigs. Ann. Neurol.4, 427–430 (1978).
   PubMedGoogle Scholar
• Boos LA, Szalai AJ, Barnum SR. Murine complement C4 is not required for experimental autoimmune encephalomyelitis. Glia49, 158–160 (2005).
   PubMedGoogle Scholar
• Nataf S, Carroll SL, Wetsel RA, Szalai AJ, Barnum SR. Attenuation of experimental autoimmune demyelination in complement-deficient mice. J. Immunol.165, 5867–5873 (2000).
   PubMedGoogle Scholar
• Davoust N, Nataf S, Reiman R, Holers MV, Campbell IL, Barnum SR. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis. J. Immunol.163, 6551–6556 (1999).
   PubMedGoogle Scholar
• Nataf S, Stahel PF, Davoust N, Barnum SR. Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci.22, 397–402 (1999).
   PubMed Web of Science ®Google Scholar
• Reiman R, Gerard C, Campbell IL, Barnum SR. Disruption of the C5a receptor gene fails to protect against experimental allergic encephalomyelitis. Eur. J. Immunol.32, 1157–1163 (2002).
   PubMedGoogle Scholar
• Reiman R, Torres AC, Martin BK, Ting JP, Campbell IL, Barnum SR. Expression of C5a in the brain does not exacerbate experimental autoimmune encephalomyelitis. Neurosci. Lett.390(3), 134–138 (2005).
   PubMedGoogle Scholar
• Morgan BP, Griffiths M, Khanom H, Taylor SM, Neal JW. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clin. Exp. Immunol.138, 430–438 (2004).
   PubMed Web of Science ®Google Scholar
• Boos L, Campbell IL, Ames R, Wetsel RA, Barnum SR. Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol.173, 4708–4714 (2004).
   PubMedGoogle Scholar
• Munoz JJ, Mackay IR. Production of experimental allergic encephalomyelitis with the aid of pertussigen in mouse strains considered genetically resistant. J. Neuroimmunol.7, 91–96 (1984).
   PubMedGoogle Scholar
• Tuohy VK, Sobel RA, Lees MB. Myelin proteolipid protein-induced experimental allergic encephalomyelitis. Variations of disease expression in different strains of mice. J. Immunol.140, 1868–1873 (1988).
   PubMed Web of Science ®Google Scholar
• Weerth SH, Rus H, Shin ML, Raine CS. Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis. Am. J. Pathol.163, 1069–1080 (2003).
   PubMed Web of Science ®Google Scholar
• Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol.168, 458–465 (2002).
   PubMed Web of Science ®Google Scholar
• Tran GT, Hodgkinson SJ, Carter N, Killingsworth M, Spicer ST, Hall BM. Attenuation of experimental allergic encephalomyelitis in complement component 6-deficient rats is associated with reduced complement C9 deposition, P-selectin expression, and cellular infiltrate in spinal cords. J. Immunol.168, 4293–4300 (2002).
   PubMed Web of Science ®Google Scholar
• Mead RJ, Neal JW, Griffiths MR et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab. Invest.84, 21–28 (2004).
   PubMed Web of Science ®Google Scholar
• Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. (Berl.)57, 239–242 (1982).
   PubMed Web of Science ®Google Scholar
• Eikelenboom P, Stam FC. An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s dementia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol.47, 17–25 (1984).
   PubMedGoogle Scholar
• Emmerling MR, Watson MD, Raby CA, Spiegel K. The role of complement in Alzheimer’s disease pathology. Biochim. Biophys. Acta1502, 158–1571 (2000).
   PubMed Web of Science ®Google Scholar
• Chaney MO, Baudry J, Esh C et al. A β, aging, and Alzheimer’s disease: a tale, models, and hypotheses. Neurol. Res.25, 581–589 (2003).
   PubMed Web of Science ®Google Scholar
• Bouras C, Riederer BM, Kovari E, Hof PR, Giannakopoulos P. Humoral immunity in brain aging and Alzheimer’s disease. Brain Res. Brain Res. Rev.48, 477–487 (2005).
   PubMed Web of Science ®Google Scholar
• Stoltzner SE, Grenfell TJ, Mori C et al. Temporal accrual of complement proteins in amyloid plaques in Down’s syndrome with Alzheimer’s disease. Am. J. Pathol.156, 489–499 (2000).
   PubMed Web of Science ®Google Scholar
• Head E, Azizeh BY, Lott IT, Tenner AJ, Cotman CW, Cribbs DH. Complement association with neurons and β-amyloid deposition in the brains of aged individuals with Down syndrome. Neurobiol. Dis.8, 252–265 (2001).
   PubMed Web of Science ®Google Scholar
• Rogers J, Cooper NR, Webster S et al. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA89, 10016–10020 (1992).
   PubMed Web of Science ®Google Scholar
• Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol.152, 5050–5059 (1994).
   PubMed Web of Science ®Google Scholar
• Watson MD, Roher AE, Kim KS, Spiegel K, Emmerling MR. Complement interactions with amyloid-β 1–42: a nidus for inflammation in AD brains. Amyloid4, 147–156 (1997).
   Web of Science ®Google Scholar
• Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: implications for Alzheimer’s disease pathogenesis. Nature Med.3, 77–79 (1997).
   PubMedGoogle Scholar
• Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer’s disease β-peptide. J. Exp. Med.188, 431–438 (1998).
   PubMed Web of Science ®Google Scholar
• Shen Y, Lue L, Yang L et al. Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neurosci. Lett.305, 165–168 (2001).
   PubMed Web of Science ®Google Scholar
• Webster S, O’Barr S, Rogers J. Enhanced aggregation and β structure of amyloid β peptide after coincubation with C1q. J. Neurosci. Res.39, 448–456 (1994).
   PubMedGoogle Scholar
• Emmerling MR, Spiegel K, Watson MD. Inhibiting the formation of classical C3-convertase on the Alzheimer's β-amyloid peptide. Immunopharmacology38, 101–109 (1997).
   PubMedGoogle Scholar
• Quigg RJ, He C, Lim A et al. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J. Exp. Med.188, 1321–1331 (1998).
   PubMedGoogle Scholar
• Wyss-Coray T, Yan F, Lin AH et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice. Proc. Natl Acad. Sci. USA99, 10837–10842 (2002).
   PubMed Web of Science ®Google Scholar
• Hsiao K, Chapman P, Nilsen S et al. Correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. Science274, 99–102 (1996).
   PubMed Web of Science ®Google Scholar
• Holcomb L, Gordon MN, McGowan E et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med.4, 97–100 (1998).
   PubMed Web of Science ®Google Scholar
• Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease. J. Neurosci.24, 6457–6465 (2004).
   PubMed Web of Science ®Google Scholar
• D’Ambrosio D, Iellem A, Colantonio L, Clissi B, Pardi R, Sinigaglia F. Localization of Th-cell subsets in inflammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol. Today21, 183–186 (2000).
   PubMedGoogle Scholar
• Riedemann NC, Ward PA. Complement in ischemia reperfusion injury. Am. J. Pathol.162, 363–367 (2003).
   PubMedGoogle Scholar
• Stahel PF, Morganti-Kossmann MC, Kossmann T. The role of the complement system in traumatic brain injury. Brain Res. Brain Res. Rev.27, 243–256 (1998).
   PubMed Web of Science ®Google Scholar
• Francis K, Van Beek J, Canova C, Neal JW, Gasque P. Innate immunity and brain inflammation: the key role of complement. Expert Rev. Mol. Med.5, 1–19 (2003).
   PubMedGoogle Scholar
• Baufreton C, Allain P, Chevailler A et al. Brain injury and neuropsychological outcome after coronary artery surgery are affected by complement activation. Ann. Thorac. Surg.79, 1597–1605 (2005).
   PubMedGoogle Scholar
• Lindsberg PJ, Ohman J, Lehto T et al. Complement activation in the central nervous system following blood-brain barrier damage in man. Ann. Neurol.40, 587–596 (1996).
   PubMed Web of Science ®Google Scholar
• Di Napoli M. Systemic complement activation in ischemic stroke. Stroke32, 1443–1448 (2001).
   PubMedGoogle Scholar
• Schultz SJ, Aly H, Hasanen BM et al. Complement component 9 activation, consumption, and neuronal deposition in the post-hypoxic-ischemic central nervous system of human newborn infants. Neurosci. Lett.378, 1–6 (2005).
   PubMedGoogle Scholar
• Van Beek J, Chan P, Bernaudin M, Petit E, MacKenzie ET, Fontaine M. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia31, 39–50 (2000).
   PubMed Web of Science ®Google Scholar
• Schafer MK, Schwaeble WJ, Post C et al. Complement C1q is dramatically up-regulated in brain microglia in response to transient global cerebral ischemia. J. Immunol.164, 5446–5452 (2000).
   PubMed Web of Science ®Google Scholar
• Huang J, Kim LJ, Mealey R et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science285, 595–599 (1999).
   PubMed Web of Science ®Google Scholar
• Ten VS, Sosunov SA, Mazer SP et al. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke36, 2244–2250 (2005).
   PubMed Web of Science ®Google Scholar
• Cowell RM, Plane JM, Silverstein FS. Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J. Neurosci.23, 9459–9468 (2003).
   PubMed Web of Science ®Google Scholar
• D’Ambrosio AL, Pinsky DJ, Connolly ES. The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection. Mol. Med.7, 367–382 (2001).
   PubMed Web of Science ®Google Scholar
• Kato H, Kogure K, Liu XH, Araki T, Itoyama Y. Progressive expression of immunomolecules on activated microglia and invading leukocytes following focal cerebral ischemia in the rat. Brain Res.734, 203–212 (1996).
   PubMed Web of Science ®Google Scholar
• Van Beek J, Bernaudin M, Petit E et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp. Neurol.161, 373–382 (2000).
   PubMed Web of Science ®Google Scholar
• Barnum SR, Ames RS, Maycox PR et al. Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation. Glia38, 169–173 (2002).
   PubMedGoogle Scholar
• Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci.26, 248–254 (2003).
   PubMed Web of Science ®Google Scholar
• Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci.22, 391–397 (1999).
   PubMed Web of Science ®Google Scholar
• Liu PK, Grossman RG, Hsu CY, Robertson CS. Ischemic injury and faulty gene transcripts in the brain. Trends Neurosci.24, 581–588 (2001).
   PubMed Web of Science ®Google Scholar
• Katsura K, Kristian T, Siesjo BK. Energy metabolism, ion homeostasis, and cell damage in the brain. Biochem. Soc. Trans.22, 991–996 (1994).
   PubMedGoogle Scholar
• Bellander BM, Singhrao SK, Ohlsson M, Mattsson P, Svensson M. Complement activation in the human brain after traumatic head injury. J. Neurotrauma18, 1295–1311 (2001).
   PubMed Web of Science ®Google Scholar
• Schmidt OI, Heyde CE, Ertel W, Stahel PF. Closed head injury – an inflammatory disease? Brain Res. Brain Res. Rev.48, 388–399 (2005).
   PubMedGoogle Scholar
• Stahel PF, Morganti-Kossmann MC, Perez D et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma18, 773–781 (2001).
   PubMed Web of Science ®Google Scholar
• Casarsa C, De Luigi A, Pausa M, De Simoni MG, Tedesco F. Intracerebroventricular injection of the terminal complement complex causes inflammatory reaction in the rat brain. Eur. J. Immunol.33, 1260–1270 (2003).
   PubMedGoogle Scholar
• Xiong ZQ, Qian W, Suzuki K, McNamara JO. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci.23, 955–960 (2003).
   PubMed Web of Science ®Google Scholar
• Kyrkanides S, O’Banion MK, Whiteley PE, Daeschner JC, Olschowka JA. Enhanced glial activation and expression of specific CNS inflammation-related molecules in aged versus young rats following cortical stab injury. J. Neuroimmunol.119, 269–277 (2001).
   PubMedGoogle Scholar
• Rancan M, Morganti-Kossmann MC, Barnum SR et al. Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. J. Cereb. Blood Flow Metab.23, 1070–1074 (2003).
   PubMedGoogle Scholar
• Keeling KL, Hicks RR, Mahesh J, Billings BB, Kotwal GJ. Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system. J. Neuroimmunol.105, 20–30 (2000).
   PubMedGoogle Scholar
• Kossmann T, Stahel PF, Morganti-Kossmann MC, Jones JL, Barnum SR. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J. Neuroimmunol.73, 63–69 (1997).
   PubMed Web of Science ®Google Scholar
• Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM. Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J. Cereb. Blood Flow Metab.15, 860–864 (1995).
   PubMedGoogle Scholar
• Sewell DL, Nacewicz B, Liu F et al. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol.155, 55–63 (2004).
   PubMed Web of Science ®Google Scholar
• Leinhase I, Schmidt OI, Thurman JM et al. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. (2006) (In Press).
   PubMedGoogle Scholar
• Quigg RJ, Kozono Y, Berthiaume D et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol.160, 4553–4560 (1998).
   PubMedGoogle Scholar
• McIntyre P. Should dexamethasone be part of routine therapy of bacterial meningitis in industrialised countries? Adv. Exp. Med. Biol.568, 189–197 (2005).
   PubMedGoogle Scholar
• Gomes JA, Stevens RD, Lewin JJ III, Mirski MA, Bhardwaj A. Glucocorticoid therapy in neurologic critical care. Crit. Care Med.33, 1214–1224 (2005).
   PubMed Web of Science ®Google Scholar
• Paul R, Koedel U, Pfister HW. Development of adjunctive therapies for bacterial meningitis and lessons from knockout mice. Neurocrit. Care2, 313–324 (2005).
   PubMedGoogle Scholar
• Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect. Dis.2, 721–736 (2002).
   PubMedGoogle Scholar
• Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J. Infect. Dis.186(Suppl. 2), S225–S233 (2002).
   PubMed Web of Science ®Google Scholar
• Stahel PF, Barnum SR. Bacterial meningitis: complement gene expression in the central nervous system. Immunopharmacology 38, 65–72 (1997).
   Google Scholar
• Brandtzaeg P, Hogasen K, Kierulf P, Mollnes TE. The excessive complement activation in fulminant meningococcal septicemia is predominantly caused by alternative pathway activation. J. Infect. Dis.173, 647–655 (1996).
   PubMedGoogle Scholar
• Johansson L, Rytkonen A, Bergman P et al. CD46 in meningococcal disease. Science301, 373–375 (2003).
   PubMed Web of Science ®Google Scholar
• Fothergill LD. Observations on the presence of complement in the cerebrospinal fluid in various pathologic conditions of the central nervous system. J. Pediatrics6, 374–381 (1935).
   Google Scholar
• Spicer S, Appelbaum E, Rutstein DD. Complement and its component fractions in cerebrospinal fluid in cerebrospinal inflammatory disease. J. Clin. Invest.28, 389–393 (1949).
   PubMedGoogle Scholar
• Faustmann PM, Krause D, Dux R, Dermietzel R. Morphological study in the early stages of complement C5a fragment- induced experimental meningitis: activation of macrophages and astrocytes. Acta Neuropathol.89, 239–247 (1995).
   PubMedGoogle Scholar
• Ernst JD, Hartiala KT, Goldstein IM, Sande MA. Complement (C5)-derived chemotactic activity accounts for accumulation of polymorphonuclear leukocytes in cerebrospinal fluid of rabbits with pneumococcal meningitis. Infect. Immun.46, 81–86 (1984).
   PubMed Web of Science ®Google Scholar
• Stahel PF, Nadal D, Pfister HW, Paradisis M, Barnum SR. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis. Lancet349, 1886–1887 (1997).
   PubMedGoogle Scholar
• Tatomirovic Z, Bokun R, Bokonjic D. Intrathecal synthesis of complement components C3c and C4 in the central nervous system infections with signs of the acute serous meningitis syndrome. Vojnosanit Pregl.59, 265–270 (2002).
   PubMedGoogle Scholar
• Mamelka B, Lobos M, Sass-Just M et al. [Does the assay of acute phase protein concentrations in cerebrospinal fluid and/or in serum in patient with viral meningitis have a diagnostic value? Part II. Lymphocytic meningitis caused by echo 30 virus]. Przegl Epidemiol.58, 351–359 (2004).
   PubMedGoogle Scholar
• Gasque P, Dean YD, McGreal EP, Van Beek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology49, 171–186 (2000).
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol.47, 707–717 (2000).
   PubMed Web of Science ®Google Scholar
• Barnum SR, Szalai AJ. Complement as a biomarker in multiple sclerosis. J. Neuropathol. Exp. Neurol.64, 741 (2005).
   PubMed Web of Science ®Google Scholar
• Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.348, 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• van Beek J, Nicole O, Ali C et al. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport12, 289–293 (2001).
   PubMedGoogle Scholar
• Heese K, Hock C, Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J. Neurochem.70, 699–707 (1998).
   PubMed Web of Science ®Google Scholar
• Francis K, Lewis BM, Akatsu H et al. Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation. Faseb. J.17, 2266–2268 (2003).
   PubMedGoogle Scholar
• Boos L, Szalai AJ, Barnum SR. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci. Lett.387, 68–71 (2005).
   PubMedGoogle Scholar
• Hicks RR, Keeling KL, Yang MY, Smith SA, Simons AM, Kotwal GJ. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma19, 705–714 (2002).
   PubMedGoogle Scholar
• Pillay NS, Kellaway LA, Kotwal GJ. Administration of vaccinia virus complement control protein shows significant cognitive improvement in a mild injury model. Ann. NY Acad. Sci.1056, 450–461 (2005).
   PubMedGoogle Scholar
• Bhole D, Stahl GL. Therapeutic potential of targeting the complement cascade in critical care medicine. Crit. Care Med.31, S97–S104 (2003).
   Web of Science ®Google Scholar
• Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol. Immunol.40, 159–170 (2003).
   PubMed Web of Science ®Google Scholar
• Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol.41, 147–152 (2004).
   PubMedGoogle Scholar
• Brook E, Herbert AP, Jenkins HT, Soares DC, Barlow PN. Opportunities for new therapies based on the natural regulators of complement activation. Ann. NY Acad. Sci.1056, 176–188 (2005).
   PubMedGoogle Scholar
• Holland MC, Morikis D, Lambris JD. Synthetic small-molecule complement inhibitors. Curr. Opin. Investig. Drugs5, 1164–1173 (2004).
   PubMedGoogle Scholar
• Bullard DC, Hu X, Schoeb TR, Axtell RC, Raman C, Barnum SR. Critical requirement of CD11b (Mac-1) on T cells and accessory cells for development of experimental autoimmune encephalomyelitis. J. Immunol.175, 6327–6333 (2005).
   PubMedGoogle Scholar